CN103830221A - Applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases - Google Patents
Applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases Download PDFInfo
- Publication number
- CN103830221A CN103830221A CN201210474879.4A CN201210474879A CN103830221A CN 103830221 A CN103830221 A CN 103830221A CN 201210474879 A CN201210474879 A CN 201210474879A CN 103830221 A CN103830221 A CN 103830221A
- Authority
- CN
- China
- Prior art keywords
- hydroxysafflor yellow
- preparation
- yellow
- applications
- cardiovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases, and more specifically relates to applications of hydroxysafflor yellow A in preparation of medicines used for treating myocardial ischemia/reperfusion injury.
Description
Summary
The invention provides the application of S-A Hydroxysafflor yellow A in the medicine of preparing Cardiovarscular, be specifically related to the application of S-A Hydroxysafflor yellow A in the medicine of preparation treatment myocardial ischemia/reperfusion injury.
Technical field
The present invention relates to the application of S-A Hydroxysafflor yellow A in preparation treatment cardiovascular diseases's medicine.
Background technology
Carthamus yellow (Safflor Yellow; SY) be the main component of Flos Carthami; mainly comprise S-A Hydroxysafflor yellow A Flos Carthami flavochrome B, there is the effect of multiple pharmacology's effects such as expansion artery, antioxidation, protection cardiac muscle, blood pressure lowering, immunosuppressant and brain protection.
The inventor finds that by a large amount of experiments S-A Hydroxysafflor yellow A has the medical usage of Cardiovarscular.
Summary of the invention
The invention provides the application of S-A Hydroxysafflor yellow A in the medicine of preparing Cardiovarscular.
The invention provides the application of S-A Hydroxysafflor yellow A in the medicine of preparation treatment myocardial ischemia/reperfusion injury.
The present invention also provides the pharmaceutical composition for cardiovascular disease taking S-A Hydroxysafflor yellow A as active component.
S-A Hydroxysafflor yellow A of the present invention is when for above-mentioned arbitrary purposes, and its using dosage scope is 30 mg～8000 mg/ days.
Pharmaceutical composition taking S-A Hydroxysafflor yellow A as active component provided by the invention, its content is 30-1000mg.It can be by oral, Sublingual, percutaneous, through muscle or subcutaneous, mucocutaneous, intravenous route administration.Can exist with forms such as injectable powder, injection, tablet, capsule, soft capsule, drop pill and oral liquids.Can be prepared from pharmacy conventional method.
The inventor has confirmed that by following test S-A Hydroxysafflor yellow A has the effect of Cardiovarscular, test S-A Hydroxysafflor yellow A used according to document [Jin Ming etc. macroporous resin column chromatography is prepared Carthamus yellow and S-A Hydroxysafflor yellow A. 01 phase of " Chinese herbal medicine " .2004] method preparation.
Detailed description of the invention:
embodiment 1:
the preparation of S-A Hydroxysafflor yellow A freeze-dried powder
Precision takes S-A Hydroxysafflor yellow A raw material 20.0g and medicinal mannitol 40.0g, is dissolved in 1000ml water for injection, is fully stirred to dissolve, with 0.1N sodium hydroxide solution adjusting pH value to 7.0, benefit injects water to 2000ml, adds pin activated carbon 2.0g, is heated to 60 DEG C and stirs 30 minutes, carbon-point filters, filtrate, through 0.25 μ m filtering with microporous membrane degerming, is sub-packed in 1000 cillin bottles, and loading amount 2.0ml/ props up, lyophilization, to obtain final product.Every hydroxyl carthamin yellow A-containing 20mg.
embodiment 2:
the preparation of S-A Hydroxysafflor yellow A injection
Precision takes S-A Hydroxysafflor yellow A raw material 20.0g, is dissolved in 1000ml water for injection, is fully stirred to dissolve, with 0.1N sodium hydroxide solution adjusting pH value to 7.0, mend and inject water to 2000ml, add pin activated carbon 2.0g, being heated to 60 DEG C stirs 30 minutes, carbon-point filters, and filtrate, through 0.25 μ m filtering with microporous membrane degerming, is sub-packed in 1000 cillin bottles, loading amount 2.0ml/ props up, sealing, sterilizing, to obtain final product.Every hydroxyl carthamin yellow A-containing 20mg.
test example 1: the impact of S-A Hydroxysafflor yellow A on coronary artery ligation rat physical signs
4.1 test material
Regular grade SD rat, male, body weight 250～300 g.
Flos Carthami injection: Wanrong three nine-day periods after the winter solstice pharmaceutcal corporation, Ltd, specification 5 ml/ prop up.
Given the test agent: method preparation to specifications.
Electrocardiograph: one-channel electrocardiograph (FX-2111), Feitian, Beijing electronic medical instruments company limited
4.2 methods and result
Get 60 of male and healthy rats, be divided at random 6 groups, model group gives isopyknic normal saline, Flos Carthami injection group is by 7.5 ml/kg tail vein injection administrations, S-A Hydroxysafflor yellow A group is respectively by 3 mg/kg, 9 mg/kg, 27 mg/kg, 81 mg/kg dosage tail vein injection administrations, administration 10 min pneumoretroperitoneums are injected 20% urethane 1.2 g/kg anesthesia, and back of the body position is fixing, records normal ECG.Chest unhairing, sterilization, along left mid-clavicular line longitudinal incision skin approximately 2 cm, in the 4th or the 5th intercostal passivity
Separate flesh layer, open thoracic cavity, cut off pericardium, gently press right side thorax, extrude heart, crown between arterial cone and left auricle
After vein place ligation left coronary artery, heart is put back to thoracic cavity, sew up rapidly thoracic wall, this operation completed in 30 seconds.After recording ischemia, electrocardiogram changes.
Data are used
± SD represents, and with model group comparison, carry out statistical procedures with t inspection.
The impact that table 2. S-A Hydroxysafflor yellow A is ordered on coronary artery ligation Rat Ecg J
* represent and model group comparison * p<0.05, * * p<0.01
Result shows, with relatively S-A Hydroxysafflor yellow A group (3 mg/kg, 9 mg/kg, 27 mg/kg, 81 mg/kg) of model group
60 min all can obviously reduce the amplitude that J point raises (
p<0.05).Along with the increase of dosage, S-A Hydroxysafflor yellow A pair, the improvement effect of myocardial ischemia also significantly improves.
2.3 conclusion
S-A Hydroxysafflor yellow A has protective effect to cardiac muscle, can reduce the myocardial damage that ischemia causes.
Claims (4)
1. the application of S-A Hydroxysafflor yellow A in the medicine of preparing Cardiovarscular.
2. the application of S-A Hydroxysafflor yellow A in the medicine of preparation treatment myocardial ischemia/reperfusion injury.
3. the pharmaceutical composition for cardiovascular disease taking S-A Hydroxysafflor yellow A as active component.
4. pharmaceutical composition according to claim 3, its content is 30-1000mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210474879.4A CN103830221A (en) | 2012-11-21 | 2012-11-21 | Applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210474879.4A CN103830221A (en) | 2012-11-21 | 2012-11-21 | Applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103830221A true CN103830221A (en) | 2014-06-04 |
Family
ID=50794328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210474879.4A Pending CN103830221A (en) | 2012-11-21 | 2012-11-21 | Applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830221A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306366A (en) * | 2014-10-22 | 2015-01-28 | 吉林大学 | Application of hydroxysafflor yellow in medicine for preventing and treating influenza |
| CN108392486A (en) * | 2018-01-23 | 2018-08-14 | 滨州医学院 | Applications of the Sydroxy carthamin B in terms of preventing myocardial ischemia-reperfusion injury |
-
2012
- 2012-11-21 CN CN201210474879.4A patent/CN103830221A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306366A (en) * | 2014-10-22 | 2015-01-28 | 吉林大学 | Application of hydroxysafflor yellow in medicine for preventing and treating influenza |
| CN108392486A (en) * | 2018-01-23 | 2018-08-14 | 滨州医学院 | Applications of the Sydroxy carthamin B in terms of preventing myocardial ischemia-reperfusion injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940000234B1 (en) | Novel pharmaceutical composition having an antitumor activity and a process for preparation thereof | |
| CN104587260A (en) | Composition of bamboo leaf flavonoid and chitosan oligosaccharide, as well as preparation method and application thereof | |
| CN108210818B (en) | Pharmaceutical composition for preventing and treating neurodegenerative diseases and preparation method and application thereof | |
| CN104719874A (en) | Ganoderma lucidum full-ingredient mixed chewable tablets and preparation method thereof | |
| CN102048821B (en) | Method for preparing perhexiline pharmaceutical preparation | |
| CN102008497A (en) | Application of catalpol in preparing drug for treating cardiac failure disease | |
| KR100312622B1 (en) | Stabilized anticancer composition mainly composed of herbal medicine and its manufacturing method | |
| CN103054883B (en) | Medicine composition containing fructose sodium diphosphate compound | |
| CN103830221A (en) | Applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases | |
| CN102274260A (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| CN104997823A (en) | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof | |
| CN103830255A (en) | Application of paeoniflorin in preparation of medicines for treating cerebrovascular diseases | |
| CN102058599B (en) | Salvianolate, and preparation method and application thereof | |
| CN100352480C (en) | Pharmaceutical composition, its preparation method and usage | |
| CN101032534B (en) | Method of preparing Ilex rotunda Thunb total saponins and the application thereof | |
| CN105311040A (en) | Fructose diphosphate containing novel pharmaceutical composition injection for treating circulation system diseases | |
| CN101019824B (en) | Preparation method of oral medicine composition containing salvianolic acid | |
| CN107875350B (en) | A Chinese medicinal composition for treating diabetes | |
| CN103127106B (en) | Purpose of phencynonate hydrochloride for treating or relieving myocardial damage induced by myocardial ischemia reperfusion and pharmaceutical compositions including phencynonate hydrochloride | |
| CN107951885B (en) | A kind of combination of oral medication for treating capillary leak syndrome | |
| CN107213254A (en) | Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared | |
| CN113967220B (en) | Pharmaceutically active composition with acute myocardial infarction curative effect | |
| CN101904860B (en) | Composite of hydrochloric acid cyclovimbuxine D and breviscapine | |
| CN100444851C (en) | Use of chrysanthemum total flavone for preparing drugs for treating arythmia | |
| CN107213154B (en) | Nursing pharmaceutical composition for promoting postoperative anesthesia and arousal and nerve injury protection and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |